Arbutus Biopharma Corporation filings document a Nasdaq-listed clinical-stage biopharmaceutical issuer with common shares without par value and a business focused on chronic hepatitis B therapeutics and lipid nanoparticle intellectual property. Form 8-K reports cover financial results, FDA Fast Track designation for imdusiran, material agreements, court orders, patent proceedings involving LNP delivery technology, and licensing or settlement matters with Genevant Sciences.
The company’s proxy materials describe annual shareholder meeting matters, board governance, executive compensation, voting procedures, and related corporate approvals. Its regulatory disclosures also connect clinical and regulatory updates for imdusiran with capital-structure, risk, intellectual-property, and operating-result reporting.
Arbutus Biopharma Corporation amended its issuer tender-offer statement to add notice of a September 30, 2026 press release announcing preliminary results of its offer, which expired September 29, 2026, at 5:00 p.m. New York City time.
The offer sought to purchase common shares for an aggregate purchase price not exceeding US$230 million, at US$5.00 to US$5.75 per share in cash, without interest.
Arbutus Biopharma Corp (ABUS) President and CEO Lindsay Androski exercised stock options on September 18, 2026, acquiring 116,408 common shares at an exercise price of $3.20 per share and 10,456 common shares at $4.39 per share. The issuer withheld 82,527 shares, reported at $5.07 per share, to satisfy the aggregate exercise prices. No Rule 10b5-1 plan is reported.
Arbutus Biopharma Corp (ABUS) Chief Financial Officer Nguyen Tuan exercised options on September 18, 2026, for 265,625 common shares at an exercise price of $3.49 per share and 27,475 common shares at an exercise price of $4.39 per share. The issuer withheld 206,637 shares otherwise issuable upon the exercises to satisfy the aggregate exercise prices. The options represented rights to purchase 750,000 and 188,400 shares, respectively, and vest subject to continuous service.
On September 18, 2026, Arbutus Biopharma Corp director Roger Sawhney exercised options to acquire 52,533 common shares at $3.34 and 78,800 common shares at $4.24. The issuer withheld 100,508 shares otherwise issuable upon the exercises to satisfy the aggregate exercise prices. The 52,533-share exercise related to an option for 157,600 shares that vests in thirds on the first three anniversaries of August 4, 2025, subject to continuous service; the 78,800-share option was fully vested and exercisable as of its June 8, 2026 grant date.
Arbutus Biopharma Corp (ABUS) director Robert A. Beardsley exercised options for 52,533 shares at an exercise price of $3.20 and 78,800 shares at $4.24 on September 18, 2026. The first option covers 157,600 shares and vests over three years, subject to continuous service; the second option was fully vested and exercisable as of June 8, 2026. The issuer withheld 99,057 shares to satisfy the aggregate exercise prices. No Rule 10b5-1 plan is reported.
Arbutus Biopharma Corp (ABUS) is the subject of a Schedule 13G filed by a group of Whitefort Capital entities and individuals David Salanic and Joseph Kaplan. As of September 4, 2026, the group reports beneficial ownership of 15,794,261 common shares, representing approximately 8.0% of Arbutus’s outstanding common shares, based on 198,105,743 shares outstanding as of August 19, 2026. The shares are held with shared voting and dispositive power through Whitefort Capital Master Fund, LP, with related general partners and managers "deemed" beneficial owners. The filers state they no longer hold the securities with a purpose or effect of changing or influencing control of Arbutus and therefore report on Schedule 13G in accordance with Rule 13d-1(h).
Arbutus Biopharma Corporation (ABUS) has launched an issuer tender offer to repurchase for cash up to US$230 million in value of its common shares. The offer is made on the terms set out in an Offer to Purchase and accompanying Issuer Bid Circular and related Letter of Transmittal.
As of August 19, 2026, 198,105,743 common shares were issued and outstanding; this is a baseline figure, not the amount being sought in the offer. The company states that it will fund purchases of shares, including related fees and expenses, from available cash on hand, and that the consideration consists solely of cash.
Arbutus Biopharma Corp (ABUS) announced plans to launch a modified “Dutch auction” issuer tender offer to repurchase up to US$230 million of its common shares. Shareholders will be able to tender shares within a price range of US$5.00 to US$5.75 per share.
The company stated that the tender offer has not yet commenced and may not proceed on these terms or at all. Upon commencement, Arbutus will file a Schedule TO with U.S. and Canadian regulators, and the offer will be made only through the formal offer to purchase, issuer bid circular, letter of transmittal and related documents.
Arbutus Biopharma Corporation (ABUS) announced plans to launch a modified “Dutch auction” tender offer to repurchase up to US$230 million of its common shares. The company expects to offer shareholders the opportunity to tender shares within a price range of US$5.00 to US$5.75 per share.
The offer is expected to commence on or about August 24, 2026 and, unless extended or terminated, expire on or about September 29, 2026. It is expected to be funded using the company’s cash on hand, including proceeds associated with a March 2026 settlement with Moderna and an initial payment received in July 2026.
Arbutus states that the offer has not yet commenced and is subject to obtaining certain exemptive relief under U.S. and Canadian securities laws, including for a proportionate tender feature and certain extension requirements. The company plans to file a Schedule TO and related offer documents when the tender offer begins.
Morgan Stanley and Morgan Stanley Investment Management Inc. report significant beneficial ownership positions in Arbutus Biopharma Corp common shares. As of June 30, 2026, certain Morgan Stanley reporting units beneficially own 17,387,398 Arbutus common shares, representing 8.8% of the class, all with shared voting and dispositive power and no sole power.
Morgan Stanley Investment Management Inc. separately reports beneficial ownership of 17,122,142 Arbutus common shares, representing 8.7% of the class, also entirely with shared voting and dispositive power. The filing notes that it covers only specified Morgan Stanley reporting units and may exclude other units whose holdings are disaggregated under SEC Release No. 34-39538.